These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 26810651)

  • 1. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
    Bekker A; Schaaf HS; Draper HR; van der Laan L; Murray S; Wiesner L; Donald PR; McIlleron HM; Hesseling AC
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2171-9. PubMed ID: 26810651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
    Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
    Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
    van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
    Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
    Babalik A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildizi L; Capaner E
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5740-2. PubMed ID: 23979746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
    Tostmann A; Mtabho CM; Semvua HH; van den Boogaard J; Kibiki GS; Boeree MJ; Aarnoutse RE
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
    Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s.
    Van Schalkwyk M; Bekker A; Decloedt E; Wang J; Theron GB; Cotton MF; Eke AC; Cressey TR; Shapiro DE; Bacon K; Knowles K; George K; Browning R; Chakhtoura N; Rungruengthanakit K; Wiesner L; Capparelli EV; Stek AM; Mirochnick M; Best BM;
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0073723. PubMed ID: 37882552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
    Thee S; Seddon JA; Donald PR; Seifart HI; Werely CJ; Hesseling AC; Rosenkranz B; Roll S; Magdorf K; Schaaf HS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5560-7. PubMed ID: 21968358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV.
    Abdelwahab MT; Leisegang R; Dooley KE; Mathad JS; Wiesner L; McIlleron H; Martinson N; Waja Z; Letutu M; Chaisson RE; Denti P
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana.
    Chideya S; Winston CA; Peloquin CA; Bradford WZ; Hopewell PC; Wells CD; Reingold AL; Kenyon TA; Moeti TL; Tappero JW
    Clin Infect Dis; 2009 Jun; 48(12):1685-94. PubMed ID: 19432554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
    Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
    Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
    Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
    Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
    Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM
    Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children.
    Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
    BMC Infect Dis; 2015 Mar; 15():126. PubMed ID: 25887748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection.
    Kwara A; Enimil A; Gillani FS; Yang H; Sarfo AM; Dompreh A; Ortsin A; Osei-Tutu L; Kwarteng Owusu S; Wiesner L; Norman J; Kurpewski J; Peloquin CA; Ansong D; Antwi S
    J Pediatric Infect Dis Soc; 2016 Dec; 5(4):356-365. PubMed ID: 26407268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.